Annual CFO
-$237.47 M
+$42.55 M+15.19%
December 31, 2024
Summary
- As of March 12, 2025, TVTX annual cash flow from operations is -$237.47 million, with the most recent change of +$42.55 million (+15.19%) on December 31, 2024.
- During the last 3 years, TVTX annual CFO has fallen by -$222.68 million (-1505.43%).
- TVTX annual CFO is now -3307.82% below its all-time high of $7.40 million, reached on December 31, 2017.
Performance
TVTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$35.72 M
+$6.79 M+15.97%
December 1, 2024
Summary
- As of March 12, 2025, TVTX quarterly cash flow from operations is -$35.72 million, with the most recent change of +$6.79 million (+15.97%) on December 1, 2024.
- Over the past year, TVTX quarterly CFO has increased by +$34.75 million (+49.31%).
- TVTX quarterly CFO is now -211.41% below its all-time high of $32.06 million, reached on September 30, 2021.
Performance
TVTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$237.47 M
+$34.75 M+12.77%
December 1, 2024
Summary
- As of March 12, 2025, TVTX TTM cash flow from operations is -$237.47 million, with the most recent change of +$34.75 million (+12.77%) on December 1, 2024.
- Over the past year, TVTX TTM CFO has increased by +$42.55 million (+15.19%).
- TVTX TTM CFO is now -3307.82% below its all-time high of $7.40 million, reached on December 31, 2017.
Performance
TVTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
TVTX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +15.2% | +49.3% | +15.2% |
| 3 y3 years | -1505.4% | +49.3% | +15.2% |
| 5 y5 years | -307.9% | +49.3% | +15.2% |
TVTX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -1505.4% | +15.2% | -32.9% | +70.0% | -1505.4% | +25.3% |
| 5 y | 5-year | -1505.4% | +15.2% | -211.4% | +70.0% | <-9999.0% | +25.3% |
| alltime | all time | -3307.8% | +15.2% | -211.4% | +70.0% | -3307.8% | +25.3% |
Travere Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$237.47 M(-15.2%) | - | - |
| Dec 2024 | - | -$35.72 M(-16.0%) | -$237.47 M(-12.8%) |
| Sep 2024 | - | -$42.51 M(+5.6%) | -$272.23 M(-5.8%) |
| Jun 2024 | - | -$40.24 M(-66.2%) | -$288.86 M(-9.1%) |
| Mar 2024 | - | -$119.00 M(+68.9%) | -$317.91 M(+13.5%) |
| Dec 2023 | -$280.02 M(+50.3%) | -$70.47 M(+19.2%) | -$280.02 M(+6.0%) |
| Sep 2023 | - | -$59.13 M(-14.7%) | -$264.19 M(+8.0%) |
| Jun 2023 | - | -$69.30 M(-14.6%) | -$244.58 M(+15.3%) |
| Mar 2023 | - | -$81.12 M(+48.5%) | -$212.09 M(+13.8%) |
| Dec 2022 | -$186.29 M(+1159.4%) | -$54.64 M(+38.2%) | -$186.29 M(+17.5%) |
| Sep 2022 | - | -$39.52 M(+7.4%) | -$158.53 M(+82.3%) |
| Jun 2022 | - | -$36.81 M(-33.5%) | -$86.94 M(+99.2%) |
| Mar 2022 | - | -$55.32 M(+105.8%) | -$43.64 M(+195.0%) |
| Dec 2021 | -$14.79 M(-65.4%) | -$26.88 M(-183.8%) | -$14.79 M(+728.7%) |
| Sep 2021 | - | $32.06 M(+393.6%) | -$1.78 M(-93.4%) |
| Jun 2021 | - | $6.50 M(-124.5%) | -$27.11 M(-32.3%) |
| Mar 2021 | - | -$26.47 M(+90.9%) | -$40.06 M(-6.3%) |
| Dec 2020 | -$42.74 M(-26.6%) | -$13.87 M(-305.9%) | -$42.74 M(+28.1%) |
| Sep 2020 | - | $6.74 M(-204.4%) | -$33.37 M(-38.5%) |
| Jun 2020 | - | -$6.45 M(-77.9%) | -$54.22 M(-18.9%) |
| Mar 2020 | - | -$29.16 M(+549.0%) | -$66.88 M(+14.9%) |
| Dec 2019 | -$58.21 M(+133.2%) | -$4.49 M(-68.2%) | -$58.21 M(+1.6%) |
| Sep 2019 | - | -$14.12 M(-26.1%) | -$57.29 M(+21.7%) |
| Jun 2019 | - | -$19.11 M(-6.7%) | -$47.06 M(+53.2%) |
| Mar 2019 | - | -$20.49 M(+474.8%) | -$30.72 M(+23.1%) |
| Dec 2018 | -$24.96 M(-437.1%) | -$3.56 M(-8.6%) | -$24.96 M(+12.2%) |
| Sep 2018 | - | -$3.90 M(+41.3%) | -$22.25 M(+83.1%) |
| Jun 2018 | - | -$2.76 M(-81.3%) | -$12.15 M(+209.6%) |
| Mar 2018 | - | -$14.73 M(+1625.3%) | -$3.92 M(-153.0%) |
| Dec 2017 | $7.40 M | -$854.00 K(-113.8%) | $7.40 M(-3236.9%) |
| Sep 2017 | - | $6.20 M(+13.4%) | -$236.00 K(-86.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | $5.47 M(-260.4%) | -$1.80 M(-45.0%) |
| Mar 2017 | - | -$3.41 M(-59.9%) | -$3.28 M(-4.6%) |
| Dec 2016 | -$3.44 M(+147.7%) | -$8.49 M(-283.5%) | -$3.44 M(-329.4%) |
| Sep 2016 | - | $4.63 M(+16.0%) | $1.50 M(-162.8%) |
| Jun 2016 | - | $3.99 M(-211.9%) | -$2.39 M(-245.9%) |
| Mar 2016 | - | -$3.57 M(+0.4%) | $1.64 M(-217.9%) |
| Dec 2015 | -$1.39 M(-97.0%) | -$3.55 M(-580.6%) | -$1.39 M(-80.0%) |
| Sep 2015 | - | $739.00 K(-90.8%) | -$6.93 M(-70.1%) |
| Jun 2015 | - | $8.02 M(-221.6%) | -$23.17 M(-45.7%) |
| Mar 2015 | - | -$6.59 M(-27.5%) | -$42.64 M(-7.0%) |
| Dec 2014 | -$45.85 M(+160.7%) | -$9.10 M(-41.3%) | -$45.85 M(+2.1%) |
| Sep 2014 | - | -$15.50 M(+35.4%) | -$44.90 M(+40.1%) |
| Jun 2014 | - | -$11.45 M(+16.8%) | -$32.06 M(+40.5%) |
| Mar 2014 | - | -$9.81 M(+20.4%) | -$22.82 M(+29.7%) |
| Dec 2013 | -$17.59 M(+542.7%) | -$8.15 M(+206.8%) | -$17.59 M(+86.3%) |
| Sep 2013 | - | -$2.66 M(+20.2%) | -$9.44 M(+39.1%) |
| Jun 2013 | - | -$2.21 M(-51.8%) | -$6.79 M(+48.2%) |
| Mar 2013 | - | -$4.58 M(<-9900.0%) | -$4.58 M(<-9900.0%) |
| Dec 2012 | -$2.74 M(<-9900.0%) | - | - |
| Nov 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| Aug 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| May 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| Feb 2012 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Feb 2012 | $0.00(-100.0%) | - | - |
| Nov 2011 | - | $0.00(0.0%) | -$600.00(-14.3%) |
| Aug 2011 | - | $0.00(0.0%) | -$700.00(0.0%) |
| May 2011 | - | $0.00(-100.0%) | -$700.00(0.0%) |
| Feb 2011 | -$700.00 | -$600.00(+500.0%) | -$700.00(+600.0%) |
| Nov 2010 | - | -$100.00(<-9900.0%) | -$100.00(<-9900.0%) |
| Aug 2010 | - | $0.00(0.0%) | $0.00(0.0%) |
| May 2010 | - | $0.00 | $0.00 |
FAQ
- What is Travere Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Travere Therapeutics?
- What is Travere Therapeutics annual CFO year-on-year change?
- What is Travere Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Travere Therapeutics?
- What is Travere Therapeutics quarterly CFO year-on-year change?
- What is Travere Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Travere Therapeutics?
- What is Travere Therapeutics TTM CFO year-on-year change?
What is Travere Therapeutics annual cash flow from operations?
The current annual CFO of TVTX is -$237.47 M
What is the all time high annual CFO for Travere Therapeutics?
Travere Therapeutics all-time high annual cash flow from operations is $7.40 M
What is Travere Therapeutics annual CFO year-on-year change?
Over the past year, TVTX annual cash flow from operations has changed by +$42.55 M (+15.19%)
What is Travere Therapeutics quarterly cash flow from operations?
The current quarterly CFO of TVTX is -$35.72 M
What is the all time high quarterly CFO for Travere Therapeutics?
Travere Therapeutics all-time high quarterly cash flow from operations is $32.06 M
What is Travere Therapeutics quarterly CFO year-on-year change?
Over the past year, TVTX quarterly cash flow from operations has changed by +$34.75 M (+49.31%)
What is Travere Therapeutics TTM cash flow from operations?
The current TTM CFO of TVTX is -$237.47 M
What is the all time high TTM CFO for Travere Therapeutics?
Travere Therapeutics all-time high TTM cash flow from operations is $7.40 M
What is Travere Therapeutics TTM CFO year-on-year change?
Over the past year, TVTX TTM cash flow from operations has changed by +$42.55 M (+15.19%)